New Version,Manufacturer

The landscape of liraglutide manufacturing has seen significant evolution, particularly with the advent of generic versions. Initially, Novo Nordisk was the primary manufacturer of liraglutide, marketing it under the brand names Victoza® for type 2 diabetes and Saxenda® for weight management. However, the market has expanded, with several other pharmaceutical companies now producing and distributing liraglutide injections. Understanding these manufacturers and their offerings is crucial for patients seeking this medication.

Novo Nordisk, a leading global healthcare company founded in 1923 and headquartered in Denmark, has been at the forefront of GLP-1 receptor agonist development. Their dedication to driving change to defeat diabetes and other serious chronic diseases has led to the creation of liraglutide. Novo Nordisk continues to be a significant player, producing both the branded Victoza® and Saxenda® and also engaging in agreements for authorized generics. It's important to note that in some instances, Teva's generic liraglutide and brand-name Victoza® are manufactured by Novo Nordisk, highlighting a collaborative approach in the market.

The introduction of generic liraglutide has increased accessibility and affordability. Teva Pharmaceuticals, Inc., a US affiliate of Teva Pharmaceutical Industries Ltd., has been a prominent entrant in this space. Teva announced the launch of the generic formulation of liraglutide in the United States, marking a significant step. They have launched authorized generics of Victoza® and also the first generic GLP-1 treatment indicated for weight loss, the generic version of Saxenda®. Teva Pharmaceuticals has officially launched generic liraglutide injections in the United States, making it available for patients with type 2 diabetes.

Another key manufacturer that has received FDA approval for its generic liraglutide is Hikma Pharmaceuticals PLC. Hikma Pharmaceuticals USA Inc. was granted FDA approval for its generic liraglutide injection, making it a significant contributor to the availability of affordable liraglutide. Hikma, the multinational pharmaceutical company, has launched its generic version of Victoza®, Liraglutide Injection, in specific dosages.

Furthermore, Meitheal Pharmaceuticals has also entered the generic liraglutide market. Meitheal Pharmaceuticals announced the launch of its liraglutide injection in April 2025, with initial pack sizes and plans for additional ones later in the year. This expansion by Meitheal further diversifies the options available to patients.

While Novo Nordisk, Teva, Hikma Pharmaceuticals, and Meitheal Pharmaceuticals are prominent names, other entities might also be involved in the manufacturing chain or in specific regions. For instance, Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) is listed as a manufacturer for Liraglutide, Injection, solution.

The primary uses for liraglutide include managing blood sugar in adults with type 2 diabetes, often in conjunction with diet and exercise. Liraglutide injection is used with diet and exercise to lower blood sugar in people with type 2 diabetes. It is also prescribed to reduce the risk of cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. For weight management, liraglutide (under the brand name Saxenda®) is indicated for adults with obesity or overweight who also have weight-related comorbidities. Saxenda (liraglutide) injection 3 mg is an injectable prescription medicine used for adults with obesity or overweight (excess weight) who also have weight-related conditions. It's important to remember that Victoza (liraglutide) is a medication that's injected once a day.

When considering liraglutide, patients and healthcare providers should be aware of the various manufacturers and their specific product offerings. The availability of generic options from companies like Teva Pharmaceuticals and Hikma Pharmaceuticals provides cost-effective alternatives to the branded liraglutide from Novo Nordisk. Always consult with a healthcare professional to determine the most suitable treatment plan and to understand the specific product being prescribed. The process of switching to a generic or understanding the differences between various liraglutide products is a common patient inquiry, and resources are available to help navigate these choices.